Women in Pharma – Sukhada Chaturvedi Pharmapack 2023
This year at Pharmapack 2023, we interviewed several leading women in the pharmaceutical industry about what it means to be a woman working in pharma. In the lead-up to International Women’s Day on March 8, 2023, CPHI Online is proud to highlight the women taking strides to make the industry a more inclusive and diverse workforce, and by extension an equal opportunity healthcare landscape.
We caught up with Sukhada Chaturvedi, International Account Manager at Körber, to discuss her journey through the pharmaceutical industry as a woman in STEM, and the challenges as well as strategies for creating an equal healthcare landscape.
Innovation requires diversity of gender and beyond
The female workforce, as Chaturvedi stated, faces more challenges than the male workforce in the pharmaceutical industry. Speaking from experience, Chaturvedi described having less opportunities available for women in the pharmaceutical workforce, especially in terms of divisions such as mechanics or sales. Female representation within the pharma industry should start at recruitment and the implementation of training to achieve and increase diversity within the team, she claimed.
Chaturvedi also extended the idea of diversity to other aspects of the human experience. Diversity of age, race, and background along with diversity of gender will naturally lead to a diversity of opinion – a necessary component for the pharmaceutical industry to innovate and push the future of healthcare forward. With women constituting 50% of the human population, Chaturvedi described how women bring forth 50% of new ideas and opinions to the pharmaceutical industry. “We bring more innovation, our experiences, our empath... Everything that we do in pharma is for the patients. The empathy part comes very naturally to women and I believe [bringing] that perspective would contribute a lot of changes in pharma,” Chaturvedi explained.
The future of pharma is female
“This should actually not be a topic of discussion because diversity should be the norm,” Chaturvedi proclaimed, but she remained aware that the pharmaceutical industry is still taking ‘baby steps’ to achieving true diversity and equality.
For women looking to start a career in pharmaceuticals or even for women currently working in one of the many pharmaceutical sectors, Chaturvedi encouraged all to set their sights on their goals: “I believe there is no stopping for women of any colour. Just take your passion with you, take everything else with a pinch of salt, and go for your goal.” She emphasised the importance of working together and in solidarity to strive towards individual goals – no one woman can do it alone.
She also encouraged everyone in the pharmaceutical industry, men and women of any department and position, to continue these discussions regarding gender equality. From female CEOs and managing directors to contractors to manufacturers, Chaturvedi believes that the pharma industry is still taking baby steps towards the big leap, part of which will be continuing the discussion: “I believe in the future, we will have [total gender equality] as a norm.”
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...